With regard to the mechanisms of the PD-1 engagement with PD-L1 in the development of HCC, PD-1 and PD-L1 inhibitors are widely recognized as the backbone of systemic therapies for HCC, and several main randomized clinical trials are shown in Table 1. Here, PDCD1 is linked to hepatocellular carcinoma.